Skip to main content

Table 1 Relationship between AR expression and different clinicopathological parameters in 111 breast carcinomas.

From: Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors

Patient and tumor characteristics N Median (range) p N° positive cases (score >0) (%) p
Total cases 111 69 (0–288)   83 (74.8)  
Age (years)    n.s.   n.s.
≤ 58 55 68(0–279)   44(80)  
>58 56 76(0–288)   39(69.6)  
Menopausal status    n.s.   n.s.
Premenopausal 29 92(0–279)   25(86.2)  
Postmenopausal 82 59(2–288)   58(70.4)  
Tumor size    n.s.   n.s.
T1 50 80(0–288)   40(80)  
T2 61 64(0–279)   43(70.5)  
Nodal status    n.s.   n.s.
Positive 52 53(0–273)   38(73.1)  
Negative 59 100(0–288)   45(76.3)  
Stage    n.s.   n.s.
I 32 71(0–273)   25 (78.1)  
II 51 64(0–243)   40 (78.4)  
III 28 83.5(0–288)   18 (64.3)  
Histologic grade    n.s.   n.s.
Well Dif. 30 66.5(0–273)   22(73.3)  
Mod. Dif. 57 88(0–288)   44(77.2)  
Poorly Dif. 24 40.5(0–267)   17(70.8)  
Estrogen receptor    n.s.   n.s.
Negative 52 55.5(0–273)   34(65.4)  
Positive 59 80(0–288)   49(83.1)  
Progesterone receptor    n.s.   n.s.
Negative 59 58(0–279)   41(69.5)  
Positive 52 76(0–288)   42(80.8)  
Desmoplastic reaction    n.s.   n.s.
No 35 48(0–270)   23(65.7)  
Yes 76 80.5(0–288)   60(78.9)  
Peritumoral inflammation    n.s.   n.s.
No 65 69.5(0–279)   48(75)  
Yes 46 86(0–288)   34(75.6)  
Tumor advancing edge    n.s.   n.s.
Expansive 49 50.5(0–270)   33(68.8)  
Infiltrating 62 84.5(0–288)   48(80)  
Vascular invasion    n.s.   n.s.
No 72 64.5(0–288)   52(72.2)  
Yes 39 81(0–279)   31(79.5)